Physician profile
Michael Banka
NPI 1013994870
$1,084.04
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $155 · 2021: $28.60 · 2022: $46.01 · 2023: $184 · 2024: $15.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $280.14 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $192.57 | 2019-2023 | |
| Amgen INC. | $136.52 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $81.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.41 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.78 | 2019-2023 | Gardasil 9, M-M-R II |
| Teva Pharmaceuticals USA, INC. | $41.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.62 | 2019 | |
| Allergan, INC. | $28.64 | 2019 | |
| Mylan Specialty L.P. | $26.57 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $20.94 | 2019 | |
| Halozyme INC | $19.60 | 2023 | |
| Tolmar, INC. | $15.61 | 2024 | |
| Radius Health, INC. | $14.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.19 | 2020 | |
| Circassia INC. | $11.55 | 2019 | |
| Shire North American Group INC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Banka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.